Pub Date : 2024-07-10DOI: 10.1016/j.ahjo.2024.100424
Namrita Ashokprabhu , Khaled Ziada , Edouard Daher , Leslie Cho , Christian W. Schmidt , Yulith Roca , Cassady Palmer , Sukhleen Kaur , Timothy D. Henry , Carl J. Pepine , Odayme Quesada
Background
In patients with angina and non-obstructive coronary artery disease (ANOCA), diagnosis of coronary microvascular dysfunction (CMD) remains an unmet need. Magnetocardiography (MCG), is a rest-based, non-invasive scan that can detect weak electrophysiological changes that occur at the early phase of ischemia.
Objective
This study assessed the ability of MCG to detect CMD in ANOCA patients as compared to reference standard, invasive coronary flow reserve (CFR).
Methods
Patients with ANOCA and invasive coronary physiologic assessment using intracoronary flow measurements with Doppler and thermodilution methods were enrolled. CMD was defined dichotomously as an invasive CFR < 2.0 by Doppler or thermodilution assessment. Noninvasive 36-channel 90-s MCG scan was performed and quantitative assessment of four distinct MCG features was completed. We evaluated the diagnostic performance of 2 or more abnormal MCG features to detect CMD in the overall cohort and performed a subgroup analysis in the subset of patients with Doppler CFR assessment.
Results
Among 79 ANOCA patients, 25 were CMD positive and 54 patients were CMD negative by CFR. Using invasive CFR as reference, MCG had an ROC AUC of 0.66 with a sensitivity of 68 % and specificity of 65 % for the detection of CMD. In the subgroup with Doppler CFR assessment, MCG had an ROC AUC of 0.76 with a sensitivity of 75 % and specificity of 77 %.
Conclusions
In ANOCA patients, MCG demonstrates the ability to detect CMD using a 90-second non-invasive scan without the need for an intravenous stressor or ionizing radiation. Further investigations are needed to validate an MCG-based diagnostic pathway for CMD.
{"title":"Evaluation of coronary microvascular dysfunction using magnetocardiography: A new application to an old technology","authors":"Namrita Ashokprabhu , Khaled Ziada , Edouard Daher , Leslie Cho , Christian W. Schmidt , Yulith Roca , Cassady Palmer , Sukhleen Kaur , Timothy D. Henry , Carl J. Pepine , Odayme Quesada","doi":"10.1016/j.ahjo.2024.100424","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100424","url":null,"abstract":"<div><h3>Background</h3><p>In patients with angina and non-obstructive coronary artery disease (ANOCA), diagnosis of coronary microvascular dysfunction (CMD) remains an unmet need. Magnetocardiography (MCG), is a rest-based, non-invasive scan that can detect weak electrophysiological changes that occur at the early phase of ischemia.</p></div><div><h3>Objective</h3><p>This study assessed the ability of MCG to detect CMD in ANOCA patients as compared to reference standard, invasive coronary flow reserve (CFR).</p></div><div><h3>Methods</h3><p>Patients with ANOCA and invasive coronary physiologic assessment using intracoronary flow measurements with Doppler and thermodilution methods were enrolled. CMD was defined dichotomously as an invasive CFR < 2.0 by Doppler or thermodilution assessment. Noninvasive 36-channel 90-s MCG scan was performed and quantitative assessment of four distinct MCG features was completed. We evaluated the diagnostic performance of 2 or more abnormal MCG features to detect CMD in the overall cohort and performed a subgroup analysis in the subset of patients with Doppler CFR assessment.</p></div><div><h3>Results</h3><p>Among 79 ANOCA patients, 25 were CMD positive and 54 patients were CMD negative by CFR. Using invasive CFR as reference, MCG had an ROC AUC of 0.66 with a sensitivity of 68 % and specificity of 65 % for the detection of CMD. In the subgroup with Doppler CFR assessment, MCG had an ROC AUC of 0.76 with a sensitivity of 75 % and specificity of 77 %.</p></div><div><h3>Conclusions</h3><p>In ANOCA patients, MCG demonstrates the ability to detect CMD using a 90-second non-invasive scan without the need for an intravenous stressor or ionizing radiation. Further investigations are needed to validate an MCG-based diagnostic pathway for CMD.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100424"},"PeriodicalIF":1.3,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000673/pdfft?md5=68a2dc70cbc1a806b2918184b6b3d367&pid=1-s2.0-S2666602224000673-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141593813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Since the beginning of the COronaVIrus Disease 2019 (COVID-19) pandemic, poor attention has been paid to the indirect effects of the pandemia on cardiovascular health system, in particular in patients with Acute Coronary Syndrome (ACS). The aims of this study is to compare possible epidemiological, clinical and management differences between the four epidemic waves in groups of patients hospitalized for ACS with a view to highlighting the burden of the pandemic on the management of this syndrome.
Materials and methods
In this retrospective observational study we included 98 patients admitted to Coronary Intensive Care Unit (CICU) for ACS between March 2020 and March 2022, who underwent revascularization procedure using percutaneous coronary angioplasty (PCI). The patients examined were divided into four groups representative of the four epidemic waves that affected our country.
Results
The rate of hospitalization for ACS increased progressively to a 178 % increase in the third wave compared to the first (p = 0.003), with an increase of 900 % if we consider only Non-ST-Elevation Myocardial Infarction (NSTEMI) (representing 54 % of the ACS diagnoses of the third group against 14.3 % in the first). Longer door-to-balloon times were recorded in the third wave for the increased presence of NSTEMI. The average hospital stay was lower in the third wave with 5 ± 2 days (p = 0.007) as well as mortality (5.1 % in the third wave; the highest in the fourth wave with 9.5 %).
Conclusions
The study show that the management of ACS suffered most from the indirect effects of the pandemic during the first wave, both because of the unpreparedness of hospital facilities and because of the fear of infection that has dissuaded people from asking for help.
{"title":"The impact of coronavirus disease 2019 on acute coronary syndrome: Differences between epidemic waves","authors":"Vincenzo Sucato, Giusy Sausa, Grazia Gambino, Alessandro D'Agostino, Salvatore Evola, Giuseppina Novo, Egle Corrado, Alfredo Ruggero Galassi","doi":"10.1016/j.ahjo.2024.100422","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100422","url":null,"abstract":"<div><h3>Introduction</h3><p>Since the beginning of the COronaVIrus Disease 2019 (COVID-19) pandemic, poor attention has been paid to the indirect effects of the pandemia on cardiovascular health system, in particular in patients with Acute Coronary Syndrome (ACS). The aims of this study is to compare possible epidemiological, clinical and management differences between the four epidemic waves in groups of patients hospitalized for ACS with a view to highlighting the burden of the pandemic on the management of this syndrome.</p></div><div><h3>Materials and methods</h3><p>In this retrospective observational study we included 98 patients admitted to Coronary Intensive Care Unit (CICU) for ACS between March 2020 and March 2022, who underwent revascularization procedure using percutaneous coronary angioplasty (PCI). The patients examined were divided into four groups representative of the four epidemic waves that affected our country.</p></div><div><h3>Results</h3><p>The rate of hospitalization for ACS increased progressively to a 178 % increase in the third wave compared to the first (<em>p</em> = 0.003), with an increase of 900 % if we consider only Non-ST-Elevation Myocardial Infarction (NSTEMI) (representing 54 % of the ACS diagnoses of the third group against 14.3 % in the first). Longer door-to-balloon times were recorded in the third wave for the increased presence of NSTEMI. The average hospital stay was lower in the third wave with 5 ± 2 days (<em>p</em> = 0.007) as well as mortality (5.1 % in the third wave; the highest in the fourth wave with 9.5 %).</p></div><div><h3>Conclusions</h3><p>The study show that the management of ACS suffered most from the indirect effects of the pandemic during the first wave, both because of the unpreparedness of hospital facilities and because of the fear of infection that has dissuaded people from asking for help.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100422"},"PeriodicalIF":1.3,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266660222400065X/pdfft?md5=dbca308cd584ec34fe47bfca389253da&pid=1-s2.0-S266660222400065X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141593782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-03DOI: 10.1016/j.ahjo.2024.100420
Rodopi Stamatiou , Georgios Kararigas
Study objective
Transgender persons face increased risk in developing cardiovascular diseases due to administration of hormonal therapy used for gender expression, or due to the presence of other risk factors, such as minority stress and difficulty to have full access to health care. Even though the need for gender diversity in research has been identified, the number of clinical trials including transgender persons remains low. The aim of this study was to highlight gaps in inclusion of transgender individuals in cardiovascular clinical research.
Design, setting
A search in the pubmed.com database, as well as in the clinicaltrials.gov repository, was performed with search terms regarding transgender persons and cardiovascular diseases.
Main outcome measure(s)
The inclusion of transgender persons in cardiovascular clinical trials was evaluated.
Results and conclusions
This study revealed that there is only a small number of cardiovascular clinical trials including or studying transgender persons. This finding demonstrates the overall lack of clinical trials regarding cardiovascular health in transgender individuals and is indicative of their under-representation in clinical research.
{"title":"Participation of transgender and gender diverse persons in cardiovascular clinical trials","authors":"Rodopi Stamatiou , Georgios Kararigas","doi":"10.1016/j.ahjo.2024.100420","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100420","url":null,"abstract":"<div><h3>Study objective</h3><p>Transgender persons face increased risk in developing cardiovascular diseases due to administration of hormonal therapy used for gender expression, or due to the presence of other risk factors, such as minority stress and difficulty to have full access to health care. Even though the need for gender diversity in research has been identified, the number of clinical trials including transgender persons remains low. The aim of this study was to highlight gaps in inclusion of transgender individuals in cardiovascular clinical research.</p></div><div><h3>Design, setting</h3><p>A search in the <span>pubmed.com</span><svg><path></path></svg> database, as well as in the <span>clinicaltrials.gov</span><svg><path></path></svg> repository, was performed with search terms regarding transgender persons and cardiovascular diseases.</p></div><div><h3>Main outcome measure(s)</h3><p>The inclusion of transgender persons in cardiovascular clinical trials was evaluated.</p></div><div><h3>Results and conclusions</h3><p>This study revealed that there is only a small number of cardiovascular clinical trials including or studying transgender persons. This finding demonstrates the overall lack of clinical trials regarding cardiovascular health in transgender individuals and is indicative of their under-representation in clinical research.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100420"},"PeriodicalIF":1.3,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000636/pdfft?md5=f12c6a1f53f4d0f3f61777a2d5e91e43&pid=1-s2.0-S2666602224000636-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141541949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-03DOI: 10.1016/j.ahjo.2024.100421
Michael I. Gurin , Yuhe Xia , Constantine Tarabanis , Randal I. Goldberg , Robert J. Knotts , Robert Donnino , Alex Reyentovich , Scott Bernstein , Lior Jankelson , Alexander Kushnir , Douglas Holmes , Michael Spinelli , David S. Park , Chirag R. Barbhaiya , Larry A. Chinitz , Anthony Aizer
Background
Catheter ablation (CA) for ventricular tachycardia (VT) can be a useful treatment strategy, however, few studies have compared CA to medical therapy (MT) in the sarcoidosis population.
Objective
To assess in-hospital outcomes and unplanned readmissions following CA for VT compared to MT in patients with sarcoidosis.
Methods
Data was obtained from the Nationwide Readmissions Database between 2010 and 2019 to identify patients with sarcoidosis admitted for VT either undergoing CA or MT during elective and non-elective admission. Primary endpoints were a composite endpoint of inpatient mortality, cardiogenic shock, cardiac arrest and 30-day hospital readmissions. Procedural complications at index admission and causes of readmission were also identified.
Results
Among 1581 patients, 1217 with sarcoidosis and VT underwent MT compared to 168 with CA during non-elective admission. 63 patients admitted electively underwent CA compared with 129 managed medically. There was no difference in the composite outcome for patients undergoing catheter ablation or medical therapy during both non-elective (9.0 % vs 12.0 %, p = 0.312) and elective admission (3.2 % vs. 7.8 %, p = 0.343). The most common cause of readmission were ventricular arrhythmias (VA) in both groups, however, those undergoing elective CA were less likely to be readmitted for VA compared to non-elective CA. The most common complication in the CA group was cardiac tamponade (4.8 %).
Conclusion
VT ablation is associated with similar rates of 30-day readmission compared to MT and does not confer increased risk of harm with respect to inpatient mortality, cardiogenic shock or cardiac arrest. Further research is warranted to determine if a subgroup of sarcoidosis patients admitted with VT are better served with an initial conservative management strategy followed by VT ablation.
{"title":"Catheter ablation compared to medical therapy for ventricular tachycardia in sarcoidosis: nationwide outcomes and hospital readmissions","authors":"Michael I. Gurin , Yuhe Xia , Constantine Tarabanis , Randal I. Goldberg , Robert J. Knotts , Robert Donnino , Alex Reyentovich , Scott Bernstein , Lior Jankelson , Alexander Kushnir , Douglas Holmes , Michael Spinelli , David S. Park , Chirag R. Barbhaiya , Larry A. Chinitz , Anthony Aizer","doi":"10.1016/j.ahjo.2024.100421","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100421","url":null,"abstract":"<div><h3>Background</h3><p>Catheter ablation (CA) for ventricular tachycardia (VT) can be a useful treatment strategy, however, few studies have compared CA to medical therapy (MT) in the sarcoidosis population.</p></div><div><h3>Objective</h3><p>To assess in-hospital outcomes and unplanned readmissions following CA for VT compared to MT in patients with sarcoidosis.</p></div><div><h3>Methods</h3><p>Data was obtained from the Nationwide Readmissions Database between 2010 and 2019 to identify patients with sarcoidosis admitted for VT either undergoing CA or MT during elective and non-elective admission. Primary endpoints were a composite endpoint of inpatient mortality, cardiogenic shock, cardiac arrest and 30-day hospital readmissions. Procedural complications at index admission and causes of readmission were also identified.</p></div><div><h3>Results</h3><p>Among 1581 patients, 1217 with sarcoidosis and VT underwent MT compared to 168 with CA during non-elective admission. 63 patients admitted electively underwent CA compared with 129 managed medically. There was no difference in the composite outcome for patients undergoing catheter ablation or medical therapy during both non-elective (9.0 % vs 12.0 %, <em>p</em> = 0.312) and elective admission (3.2 % vs. 7.8 %, <em>p</em> = 0.343). The most common cause of readmission were ventricular arrhythmias (VA) in both groups, however, those undergoing elective CA were less likely to be readmitted for VA compared to non-elective CA. The most common complication in the CA group was cardiac tamponade (4.8 %).</p></div><div><h3>Conclusion</h3><p>VT ablation is associated with similar rates of 30-day readmission compared to MT and does not confer increased risk of harm with respect to inpatient mortality, cardiogenic shock or cardiac arrest. Further research is warranted to determine if a subgroup of sarcoidosis patients admitted with VT are better served with an initial conservative management strategy followed by VT ablation.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100421"},"PeriodicalIF":1.3,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000648/pdfft?md5=adee334be461cc6e02a7a9bcd943a566&pid=1-s2.0-S2666602224000648-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141594885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.ahjo.2024.100415
{"title":"In memoriam","authors":"","doi":"10.1016/j.ahjo.2024.100415","DOIUrl":"10.1016/j.ahjo.2024.100415","url":null,"abstract":"","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100415"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000582/pdfft?md5=b482b69f6625f820440c904953d96342&pid=1-s2.0-S2666602224000582-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141636543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-28DOI: 10.1016/j.ahjo.2024.100417
Enrui Xie , Xiaotao Shen , Yee Hui Yeo , Zixuan Xing , Joseph E. Ebinger , Yixuan Duan , Yue Zhang , Susan Cheng , Fanpu Ji , Jie Deng
An increase in acute myocardial infarction (AMI)-related deaths has been reported during the COVID-19 pandemic. Despite evidence suggesting the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and AMI, the underlying mechanisms remain unclear. Here, we integrated mRNA and microRNA expression profiles related to SARS-CoV-2 infection and AMI from public databases. We then performed transcriptomic analysis using bioinformatics and systems biology approaches to explore the potential molecular mechanisms of SARS-CoV-2 infection affects AMI. First, twenty-one common differentially expressed genes (DEGs) were identified from SARS-CoV-2 infection and AMI patients in endothelial cells datasets and then we performed functional analysis to predict the roles of these DEGs. The functional analysis emphasized that the endothelial cell response to cytokine stimulus due to excessive inflammation was essential in these two diseases. Importantly, the tumor necrosis factor and interleukin-17 signaling pathways appeared to be integral factors in this mechanism. Interestingly, most of these common genes were also upregulated in transcriptomic datasets of SARS-CoV-2-infected cardiomyocytes, suggesting that these genes may be shared in cardiac- and vascular-related injuries. We subsequently built a protein-protein interaction network and extracted hub genes and essential modules from this network. At the transcriptional and post-transcriptional levels, regulatory networks with common DEGs were also constructed, and some key regulator signatures were further identified and validated. In summary, our research revealed that a highly activated inflammatory response in patients with COVID-19 might be a crucial factor for susceptibility to AMI and we identified some candidate genes and regulators that could be used as biomarkers or potential therapeutic targets.
据报道,在 COVID-19 大流行期间,与急性心肌梗死(AMI)相关的死亡人数有所增加。尽管有证据表明严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)感染与急性心肌梗死之间存在关联,但其潜在机制仍不清楚。在此,我们整合了公共数据库中与 SARS-CoV-2 感染和 AMI 相关的 mRNA 和 microRNA 表达谱。然后,我们利用生物信息学和系统生物学方法进行了转录组分析,以探索 SARS-CoV-2 感染影响 AMI 的潜在分子机制。首先,我们从SARS-CoV-2感染和AMI患者的内皮细胞数据集中发现了21个常见的差异表达基因(DEGs),然后进行了功能分析以预测这些DEGs的作用。功能分析结果表明,在这两种疾病中,内皮细胞对过度炎症导致的细胞因子刺激的反应至关重要。重要的是,肿瘤坏死因子和白细胞介素-17 信号通路似乎是这一机制中不可或缺的因素。有趣的是,在 SARS-CoV-2 感染的心肌细胞的转录组数据集中,这些常见基因中的大多数也出现了上调,这表明这些基因可能在心脏和血管相关损伤中具有共通性。随后,我们建立了一个蛋白质-蛋白质相互作用网络,并从中提取了枢纽基因和重要模块。在转录和转录后水平,我们还构建了具有共同 DEGs 的调控网络,并进一步鉴定和验证了一些关键调控因子特征。总之,我们的研究揭示了 COVID-19 患者高度激活的炎症反应可能是导致 AMI 易感性的关键因素,我们还发现了一些候选基因和调控因子,它们可用作生物标记物或潜在的治疗靶点。
{"title":"Exploring the underlying molecular mechanisms of acute myocardial infarction after SARS-CoV-2 infection","authors":"Enrui Xie , Xiaotao Shen , Yee Hui Yeo , Zixuan Xing , Joseph E. Ebinger , Yixuan Duan , Yue Zhang , Susan Cheng , Fanpu Ji , Jie Deng","doi":"10.1016/j.ahjo.2024.100417","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100417","url":null,"abstract":"<div><p>An increase in acute myocardial infarction (AMI)-related deaths has been reported during the COVID-19 pandemic. Despite evidence suggesting the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and AMI, the underlying mechanisms remain unclear. Here, we integrated mRNA and microRNA expression profiles related to SARS-CoV-2 infection and AMI from public databases. We then performed transcriptomic analysis using bioinformatics and systems biology approaches to explore the potential molecular mechanisms of SARS-CoV-2 infection affects AMI. First, twenty-one common differentially expressed genes (DEGs) were identified from SARS-CoV-2 infection and AMI patients in endothelial cells datasets and then we performed functional analysis to predict the roles of these DEGs. The functional analysis emphasized that the endothelial cell response to cytokine stimulus due to excessive inflammation was essential in these two diseases. Importantly, the tumor necrosis factor and interleukin-17 signaling pathways appeared to be integral factors in this mechanism. Interestingly, most of these common genes were also upregulated in transcriptomic datasets of SARS-CoV-2-infected cardiomyocytes, suggesting that these genes may be shared in cardiac- and vascular-related injuries. We subsequently built a protein-protein interaction network and extracted hub genes and essential modules from this network. At the transcriptional and post-transcriptional levels, regulatory networks with common DEGs were also constructed, and some key regulator signatures were further identified and validated. In summary, our research revealed that a highly activated inflammatory response in patients with COVID-19 might be a crucial factor for susceptibility to AMI and we identified some candidate genes and regulators that could be used as biomarkers or potential therapeutic targets.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100417"},"PeriodicalIF":1.3,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000600/pdfft?md5=9570bf66bd1f55b63e86eddfc1c4fa3c&pid=1-s2.0-S2666602224000600-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141483479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-25DOI: 10.1016/j.ahjo.2024.100418
Anna Vittoria Mattioli , Valentina Bucciarelli , Sabina Gallina
Teaching gender and sex differences is fundamental in medical classes because it has a strong impact in reducing disparity in treatment, in defining effective and personalized therapies that respect the different physiology and pathophysiology of women. Furthermore, it is the prerequisite for the pharmacoequity.
{"title":"Teaching gender medicine can enhance the quality of healthcare","authors":"Anna Vittoria Mattioli , Valentina Bucciarelli , Sabina Gallina","doi":"10.1016/j.ahjo.2024.100418","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100418","url":null,"abstract":"<div><p>Teaching gender and sex differences is fundamental in medical classes because it has a strong impact in reducing disparity in treatment, in defining effective and personalized therapies that respect the different physiology and pathophysiology of women. Furthermore, it is the prerequisite for the pharmacoequity.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100418"},"PeriodicalIF":1.3,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000612/pdfft?md5=19a5a4e04030ecbef15bc58b658d6e5a&pid=1-s2.0-S2666602224000612-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141478694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-25DOI: 10.1016/j.ahjo.2024.100419
Asaad Nakhle , Katherine J. Kunkel , Obadah Aqtash , Samer Zakhour , Lizbeth Brice , Jelena Arnautovic , Parth Desai , Milan Kaushik , Keith Ferdinand , Khaldoon Alaswad , Mir Babar Basir
Coronary calcified lesions are commonly encountered and coronary atherectomy is commonly used for lesion modification during percutaneous coronary interventions (PCI). The release of adenosine during atherectomy can result in bradyarrhythmias and aminophylline is commonly used to prevent this reaction. We identified 138 patients to evaluate the safety and efficacy of intravenous (IV) aminophylline administration prior to coronary atherectomy. A total of 159 calcified lesions were treated, and the atherectomy device was orbital atherectomy, rotational atherectomy, and both in 52 %, 42 %, and 6 %; respectively. After administration of aminophylline, 4.3 % of patients required intraprocedural insertion of a transvenous pacer (TVP), and 18.1 % of patients required administration of IV atropine. Technical success was achieved in 98.6 % of patients, and no adverse reactions to aminophylline were reported. All patients survived to discharge. In conclusion, aminophylline administration prior to coronary atherectomy was safe and effective. No adverse effects of aminophylline were seen, and the rate of bailout TVP placement was low.
{"title":"Safety and efficacy of aminophylline in the prevention of bradyarrhythmia during coronary atherectomy","authors":"Asaad Nakhle , Katherine J. Kunkel , Obadah Aqtash , Samer Zakhour , Lizbeth Brice , Jelena Arnautovic , Parth Desai , Milan Kaushik , Keith Ferdinand , Khaldoon Alaswad , Mir Babar Basir","doi":"10.1016/j.ahjo.2024.100419","DOIUrl":"10.1016/j.ahjo.2024.100419","url":null,"abstract":"<div><p>Coronary calcified lesions are commonly encountered and coronary atherectomy is commonly used for lesion modification during percutaneous coronary interventions (PCI). The release of adenosine during atherectomy can result in bradyarrhythmias and aminophylline is commonly used to prevent this reaction. We identified 138 patients to evaluate the safety and efficacy of intravenous (IV) aminophylline administration prior to coronary atherectomy. A total of 159 calcified lesions were treated, and the atherectomy device was orbital atherectomy, rotational atherectomy, and both in 52 %, 42 %, and 6 %; respectively. After administration of aminophylline, 4.3 % of patients required intraprocedural insertion of a transvenous pacer (TVP), and 18.1 % of patients required administration of IV atropine. Technical success was achieved in 98.6 % of patients, and no adverse reactions to aminophylline were reported. All patients survived to discharge. In conclusion, aminophylline administration prior to coronary atherectomy was safe and effective. No adverse effects of aminophylline were seen, and the rate of bailout TVP placement was low.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100419"},"PeriodicalIF":1.3,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000624/pdfft?md5=b0308a99c9f3848af18612ff0cb3615d&pid=1-s2.0-S2666602224000624-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141636542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast cancer anti-estrogen resistance-1 (p130Cas/BCAR1) is an adaptor protein of the cas(Cas) family. This protein regulates multiple complex pathways in different organs including bones, pancreas, and immune and cardiovascular systems. Although previous research well demonstrated the role of p130Cas/BCAR1 in different diseases especially cancers, a precise review study on the various effects of p130Cas/BCAR1 on cardiovascular diseases is missing. In this study, we reviewed mechanisms of action for p130Cas/BCAR1 impact, on cardiac embryonic development defects, hypertrophy and remodeling, pulmonary artery hypertension (PAH), and atherosclerosis. Also, we suggest feature direction for research and potential therapeutic implications. This study showed that p130Cas/BCAR1 can affect cardiovascular diseases in various mechanisms including actin stress fiber formation, attachment to focal adhesion kinase (FAK) and angiotensin II (Ang II), generation of reactive oxygen species (ROS), and growth factor signaling through amplifying receptor tyrosine kinase (RTKs).
{"title":"The role of p130Cas/BCAR1 adaptor protein in the pathogenesis of cardiovascular diseases: A literature review","authors":"Ghazal Ghasempour Dabaghi , Mehrdad Rabiee Rad , Reza Amani-Beni , Bahar Darouei","doi":"10.1016/j.ahjo.2024.100416","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100416","url":null,"abstract":"<div><p>Breast cancer anti-estrogen resistance-1 (p130Cas/BCAR1) is an adaptor protein of the cas(Cas) family. This protein regulates multiple complex pathways in different organs including bones, pancreas, and immune and cardiovascular systems. Although previous research well demonstrated the role of p130Cas/BCAR1 in different diseases especially cancers, a precise review study on the various effects of p130Cas/BCAR1 on cardiovascular diseases is missing. In this study, we reviewed mechanisms of action for p130Cas/BCAR1 impact, on cardiac embryonic development defects, hypertrophy and remodeling, pulmonary artery hypertension (PAH), and atherosclerosis. Also, we suggest feature direction for research and potential therapeutic implications. This study showed that p130Cas/BCAR1 can affect cardiovascular diseases in various mechanisms including actin stress fiber formation, attachment to focal adhesion kinase (FAK) and angiotensin II (Ang II), generation of reactive oxygen species (ROS), and growth factor signaling through amplifying receptor tyrosine kinase (RTKs).</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100416"},"PeriodicalIF":1.3,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000594/pdfft?md5=471cf0f54d8ed646c8163c00229e1fd3&pid=1-s2.0-S2666602224000594-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141486417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-20DOI: 10.1016/j.ahjo.2024.100414
Ruxandra Ionescu , Jared W. Magnani
Barbershops and beauty salons provide community-specific opportunities to engage in cardiovascular disease screening and prevention. This editorial articulates the advantages of what is termed the “barbershop paradigm,” the community-engaged endeavor that leverages familiarity, trust, and stakeholder engagement to advance cardiovascular health. The authors summarize the neighborhood-based factors that contribute to cardiovascular health, and then identify the strategies implemented by ShopTalk and their specific advantages.
{"title":"The barbershop paradigm: Community engagement for cardiovascular prevention","authors":"Ruxandra Ionescu , Jared W. Magnani","doi":"10.1016/j.ahjo.2024.100414","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100414","url":null,"abstract":"<div><p>Barbershops and beauty salons provide community-specific opportunities to engage in cardiovascular disease screening and prevention. This editorial articulates the advantages of what is termed the “barbershop paradigm,” the community-engaged endeavor that leverages familiarity, trust, and stakeholder engagement to advance cardiovascular health. The authors summarize the neighborhood-based factors that contribute to cardiovascular health, and then identify the strategies implemented by <em>ShopTalk</em> and their specific advantages.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100414"},"PeriodicalIF":1.3,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000570/pdfft?md5=166459f8d7d5984756045aa92a6e8fdd&pid=1-s2.0-S2666602224000570-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141434998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}